New hope for pancreatic cancer? drug combo trial launches

NCT ID NCT06844422

Recruiting now Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called ivonescimab, combined with targeted radiation and chemotherapy, for people with locally advanced pancreatic cancer that cannot be removed by surgery. The trial has two phases: first, finding the safest dose of ivonescimab, then checking how well the combination works at controlling the cancer. About 37 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab (a drug that targets PD-1 and VEGF, combined with radiation and chemotherapy)
What this could lead to: If successful, this could offer a new treatment option for people with locally advanced pancreatic cancer, potentially slowing tumor growth and improving survival.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and the drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Shandong Cancer Hospital and Institute
RECRUITING

Jinan, Shandong, 0531, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.